Anti-IL-12/23 antibody therapy reduces periodontal inflammation and gingival IL-6 in IBD patients compared to anti-TNF.
Background
Patients with Inflammatory Bowel Diseases (IBD) face an elevated risk of periodontitis, a chronic inflammatory condition affecting the gums and supporting structures of teeth. While biological therapies targeting cytokines like Tumor Necrosis Factor (TNF) and Interleukin-12/23 (IL-12/23) are crucial for managing IBD, their specific impact on periodontal health has remained largely unexplored. Understanding how these systemic immunomodulators influence oral inflammation could reveal new avenues for integrated care and improved patient outcomes, addressing a significant comorbidity gap.
Study Design
This cross-sectional, hypothesis-generating study examined 45 patients with IBD, stratifying them into three groups of n = 15 each based on their biological therapy: anti-TNF therapy, anti-IL-12/23 therapy, or a control group receiving no biologics. Periodontal status was assessed using the Periodontal Screening Index (PSI) (codes 0-4) across all sextants. Medical history and oral hygiene behaviors were also documented. To quantify local immune activity, interleukin-6 (IL-6) concentrations in gingival crevicular fluid (GCF) were measured using enzyme-linked immunosorbent assay (ELISA).
Results
Overall, 16 patients exhibited either known or previously undiagnosed periodontitis, with varying severity across individuals. Patients receiving anti-IL-12/23 therapy demonstrated lower mean and maximal Periodontal Screening Index (PSI) scores compared to those on anti-TNF therapy. Notably, no sextants with advanced periodontal inflammation (PSI 3-4) were detected in the anti-IL-12/23 group. In stark contrast, active or latent periodontitis was observed in both the anti-TNF and control cohorts. Concordantly, IL-6 levels in gingival crevicular fluid (GCF) were significantly reduced in patients undergoing IL-12/23 blockade when compared to controls, indicating attenuated local inflammatory signaling at the periodontal interface. These beneficial findings were observed despite no statistically significant differences in clinical or endoscopic IBD disease activity between the groups, suggesting a direct effect on oral inflammation.
Key Findings
- 16 out of 45 IBD patients exhibited periodontitis.
- Anti-IL-12/23 therapy group showed lower mean and maximal
Periodontal Screening Index (PSI)scores. - No sextants with advanced periodontal inflammation (
PSI 3-4) were found in the anti-IL-12/23 group. IL-6levels ingingival crevicular fluid (GCF)were significantly reduced in anti-IL-12/23 patients compared to controls.
Why It Matters
These exploratory findings suggest that systemic inhibition of the IL-12/23 axis may offer a dual benefit for IBD patients by concurrently improving periodontal health. This insight is crucial for clinicians managing IBD, as it highlights a potential systemic therapy that could mitigate a common and often overlooked comorbidity. While this study is cross-sectional, it opens the door for future prospective trials to investigate anti-IL-12/23 agents as a strategy to reduce oral inflammatory burden in IBD patients, potentially leading to integrated treatment protocols that address both gut and oral health. The data implies that specific immunomodulatory pathways, beyond just TNF blockade, have distinct impacts on localized inflammation.
ibd
periodontitis
anti-tnf
anti-il-12/23
inflammation
il-6